Pre-TCR Signaling and CD8 Gene Bivalent Chromatin Resolution during Thymocyte Development

Nicola Harker, Anna Garefalaki, Ursula Menzel, Eleni Ktistaki, Taku Naito, Katia Georgopoulos and Dimitris Kioussis

*J Immunol* 2011; 186:6368-6377; Prepublished online 22 April 2011; doi: 10.4049/jimmunol.1003567
http://www.jimmunol.org/content/186/11/6368

Supplementary Material  http://www.jimmunol.org/content/suppl/2011/04/22/jimmunol.1003567.DC1

References  This article cites 61 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/186/11/6368.full#ref-list-1

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*average

Subscription  Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

Permissions  Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts  Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Pre-TCR Signaling and CD8 Gene Bivalent Chromatin Resolution during Thymocyte Development

Nicola Harker,* Anna Garefalaki,* Ursula Menzel,* Eleni Ktistaki,* Taku Naito,† Katia Georgopoulos,‡ and Dimitris Kioussis*†

The CD8 gene is silent in CD4+CD8− double-negative thymocytes, expressed in CD4+CD8+ double-positive cells, and silenced in cells committing to the CD4+ single-positive (SP) lineage, remaining active in the CD8+ SP lineage. In this study, we show that the chromatin of the CD8 locus is remodeled in C57BL/6 and B6/J Rag1−/− MOM double-negative thymocytes as indicated by DNA sensitivity and widespread bivalent chromatin marks. Pre-TCR signaling coincides with chromatin bivalency resolution into monovalent activating modifications in double-positive and CD8 SP cells. Shortly after commitment to CD4 SP cell lineage, monovalent repressive characteristics and chromatin inaccessibility are established. Differential binding of Ikaros, NuRD, and heterochromatin protein 1 on the locus during these processes may participate in the complex regulation of CD8. The Journal of Immunology, 2011, 186: 6368–6377.

Expression of coreceptors CD4 and CD8 mark the differentiation stages of thymocyte development. CD4+CD8− T cell precursors in the thymus start expressing the pre-TCR complex, which enables them to pass the β selection checkpoint. Subsequently, the α- and β-chains of TCR and CD4 and CD8 are expressed to generate CD4+CD8+ double-positive (DP) cells that undergo positive and negative selection to ensure that only fully functional and harmless T cells are released in the periphery (reviewed in Ref. 1). On most CD8+ cells, the coreceptor is expressed as a disulphide-linked CD8α/CD8β heterodimer (2–4). The CD8α and CD8β genes are located on chromosome 6 (5), and all of the sequences required for full and appropriate expression of the CD8αβ heterodimer reside within an 80-kb genomic fragment (6). There are a growing number of proteins regulating the CD8 locus, with Ikaros, Runx1, Baf57, and Brγ implicated in the activation of transcription (7–10) and MAZR being associated with CD8 repression (11). Differentiating cells activate or silence genes implicating chromatin-remodeling processes, such as histone modifications and nucleosome displacement (12–19).

Histone modifications include trimethylation of lysine 4 of histone H3 (H3K4me3), associated with a transcriptionally permissive status (20, 21) and trimethylation of lysine 27 of histone H3 (H3K27me3) associated with repression (22). These two modifications, until recently, were deemed to be mutually exclusive. However, work by Azaara et al. (23) and Bernstein et al. (24) showed that these two marks can coexist at the promoter of a number of low or nonexpressing gene loci in mouse embryonic stem (ES) cells. This phenomenon is described as bivalency and the regions of the chromosome exhibiting these marks as bivalent chromatin. Such bivalent states were also identified at the promoter of genes of more differentiated cell types, such as naïve T cells, CD8+ memory T cells, and macrophages (25–27). Bivalency is currently considered to be an important control mechanism by which a gene locus acquires a poised configuration and is thought to be resolved in subsequent stages by the loss of one and the retention of the other of these two modifications, leading to full activation or silencing, accordingly.

In recent years, epigenetic modifications of chromatin during thymocyte development and lineage commitment have been described (9, 11, 28–31). However, it is unclear at the moment whether the mechanisms governing bivalent chromatin also apply at branching fate decision points of thymocyte differentiation (32). To address this issue, we have undertaken a kinetic DNaseI hypersensitive site analysis of the murine CD8 gene complex, as well as an assessment of its histone code and association with chromatin remodeling activities during thymocyte differentiation.

In this study, we show that partial remodeling of the CD8 locus is apparent at the double-negative (DN) 3 stage before CD8 expression. Interestingly, pre-TCR signaling at the β selection point is followed by full accessibility of the locus, whereas commitment to the CD4 lineage results in its gradual inaccessibility. Importantly, histone code analysis of the locus reveals bivalent characteristics of negative and positive marks at the DN stage, right before the locus becomes activated. We provide evidence that Ikaros associates with the locus throughout all the stages of development and that in nonexpressing cells, Ikaros plays a role in the regulation of the locus, probably either by recruiting on-site Mi-2β, a component of the negative chromatin remodeler NuRD, or by antagonizing Mi-2β.

*Division of Molecular Immunology, National Institute for Medical Research, Medical Research Council, London, NW7 1AA, United Kingdom; †Transcriptional Regulation Laboratory, RIKEN Research Center for Allergy and Immunology, Yokohama 230-0045, Japan; and ‡Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129

Received for publication October 29, 2010. Accepted for publication March 24, 2011.

This work was supported by the Medical Research Council UK (U117512796).

N.H., A.G., E.K., and U.M. performed the experiments; N.H. and D.K. designed the experiments; N.H. and D.K. wrote the manuscript; T.N. and K.G. provided scientific advice and reagents, contributed in the design of some experiments, and edited the manuscript; and D.K. directed the research.

Address correspondence and reprint requests to Dr. Nicola Harker, National Institute for Medical Research, Medical Research Council, The Ridgeway, Mill Hill, London NW7 1AA, U.K. E-mail address: nharker@nimr.mrc.ac.uk

The online version of this article contains supplemental material.

Abbreviations used in this article: ChIP, chromatin immunoprecipitation; Cp, cycle threshold; DN, double-negative; DP, double-positive; ES, embryonic stem; H3K27me3, trimethylation of lysine 27 of histone H3; H3K4me3, trimethylation of lysine 4 of histone H3; HP1α, heterochromatin protein 1α; IP, immunoprecipitation; NIMR, National Institute for Medical Research; qPCR, quantitative PCR; S2, Schneider 2; SP, single-positive.

Copyright © 2011 by The American Association of Immunologists, Inc. 0022-1767/11/$16.00

The online version of this article contains supplemental material.
Materials and Methods
Mice and cell culture
C57BL/10 (National Institute for Medical Research [NIMR]), C57BL/6 (NIMR), and B6/J Rag1−/− MOM mice (33) were housed in specific pathogen-free conditions and euthanized via a schedule 1 procedure via exposure to CO2. The authors confirm that all experiments were performed in accordance with the guidelines and regulations of the Home Office UK and the Ethics Review Panel of the Medical Research Council. Drosophila melanogaster Schneider 2 (S2) cells were grown at 28˚C without CO2 in Schneider’s Drosophila Medium (Invitrogen) with 10% heat-inactivated FBS (Bisotera).

Cell sorting
For the isolation of wild-type T cell populations, thymus and spleen were taken from 20 C57BL/6 or C57BL/10 mice and stained with the following Abs. Peripheral CD4 and CD8 single-positive (SP) T cells were stained with anti-TCRβ FITC, anti-CD4 PE, and anti-CD8 allophycocyanin; CD4 SP and CD8 SP thymocytes were stained with anti-CD4 allophycocyanin, anti-CD8 FITC, and anti-CD24 PE, and the cells were sorted as CD4+ / CD24− and CD8+ /CD24−; DP thymocytes were stained with anti-CD8 FITC and anti-CD4 allophycocyanin; B cells were stained with anti-B220. The cells were sorted using the Cytomation MoFlo high-speed cell sorter (DakoCytomation).

For the isolation of DN cells, 80 C57BL6 or C57BL/10 thymi were subjected to complement treatment prior to sorting to enrich for DN cells. Thymocytes were incubated with anti-CD4 (RL172.4; NIMR) and anti-CD8 (AD4 [15]; NIMR) Abs followed by incubation with low-tox rabbit complement and low-tox guinea pig complement (Cedarlane Laboratories). The enriched cell population was stained with anti-CD4- FITC, anti-CD23 allophycocyanin, and the following PE Abs: anti-CD4 (BD Pharmingen), anti-CD8a, anti-CD8b, anti-CD3 (E Biosciences); anti-Tcrβ (E Biosciences); anti-Ter119 (E Biosciences); and anti-CD49b (DX5), anti-CD11b (Mac1), and anti-CD45R (B220; BD Pharmingen). The cells were sorted using the Cytomation MoFlo high-speed cell sorter (DakoCytomation), gating out the PE positive fraction. All cell populations were at least 96% pure. All Abs were obtained from Caltag Laboratories unless otherwise stated.

DNasel analysis
Nuclei from C57BL/10 and B6/J Rag1−/− MOM mice were prepared using the method by Forrester and colleagues with adaptations (34). A total of 1 × 105 cells/sample were lysed in 0.5% Nonidet P-40/RSB and incubated with 1 μl CaCl2 and increasing concentrations of DNaseI (0, 20, 40, and 80 ng; Sigma-Aldrich) at 37˚C for 4 min. DNasel activity was inhibited with the addition of 100 μl DNasel stop mix (0.6 M NaCl, 20 mM Tris (pH 8), 10 mM EDTA, and 1% SDS). Following a proteinase K step, DNA was treated with RNase and digested with proteinase K; DNA was phenol extracted and ethanol precipitated in the presence of 10 μg glycogen. Samples were analyzed by real-time PCR.

Real-time PCR analysis of ChIP samples
DNA was amplified with primers spanning the CD8-hypersensitive sites: CII-1F, 5′-GTG GTT GAT ACA GGA AGT ACT C-3′; CII-1R, 5′-CTC CGA TCA TAC CAC T-3′; CII-3F (promoter), 5′-GCC AGC TAT GTG GGT CAT ATC-3′; CII-3R, 5′-GTA TCA CAG AAC GGG TGC AGG-3′; CII-2F, 5′-ACT ATG TCA GTC CAG CCA GGC C-3′; CII-2R, 5′-CTG TCT CCA ACT AGA ATG AAG C-3′; CII-3F (promoter), 5′-AAT TCC TCC TAC TCT CTC TCG-3′; CII-5′-CTC GCT TCC AAC CAA CAC ATG CTG-3′; and CII-3R, 5′-GTC TGG TGG CAT GGC CAC GAC G-3′. DNA was quantified by incorporation of SYBR Green (Applied Biosystems) on Applied Biosystems 7900HT. Cycle threshold (Ct) values for each sample was normalized to a nonhypersensitive region of the locus (EoxNv), whereas any change in product with DNasel treatment was expressed as a percentage of DNasel untreated sample.

Results
B6/J Rag1−/− MOM thymocytes exhibit a hypersensitive CD8 locus
Previously transgenic and knockout analysis had shown the importance of DNasel Hypersensitive clusters II, III, and IV (Fig. 1A, CII, CIII, CIV) for CD8α expression (6, 37–43). We present in this study a kinetic analysis of the appearance and maintenance of
hypersensitive sites during thymocyte differentiation. To investigate the status of the CD8 locus in DN thymocytes, DNaseI hypersensitivity analysis of thymocytes from B6/J Rag1<sup>−/−</sup> MOM (Rag1<sup>−/−</sup>) mice and sorted C57BL/10 wild-type total DN thymocytes was undertaken. Rag1<sup>−/−</sup> mice were used to take advantage of the high proportion of DN cells in this strain, which results from the arrest of T cell development at the β selection checkpoint.

Fig. 1B, panel 1, shows DNaseI sensitivity analysis of Rag1<sup>−/−</sup> thymocytes, indicating that the promoter of the CD8α locus (CII-3 site) is hypersensitive when transcription from the CD8 locus is undetectable (Supplemental Fig. 1). Analysis of total DN cells from C57BL/10 mice (Fig. 1B, panel 2), including post-β selection DN4 stage cells, shows that, in addition to CII-3 site, sites CII-1 and CII-2 are also detected. These data suggest that signaling through the pre-TCR results in the full remodeling of the locus before the onset of CD8 expression. In some of the cell populations, the DNaseI hypersensitivity sites are difficult to visualize on the autoradiograph, as only a small proportion of the cells have opened the CD8 locus. Thus, the DNase I hypersensitivity site bands were quantified using Quantity One software (Bio-Rad), the results of which are shown in Supplemental Fig. 2.

The CD8 locus becomes hypersensitive to DNaseI at the DN3 stage

These findings were confirmed and refined using quantitative PCR (qPCR)-DNaseI assays (Fig. 2). Use of the qPCR technique enabled thorough analysis of DN subpopulations that would otherwise be too few in number to visualize using the Southern blotting method. In addition, this enabled wild-type thymocytes to be used, ruling out any possibility of aberrant results that could be attributed to the Rag1<sup>−/−</sup> phenotype rather than the particular cell population.

DN subpopulations from B6 mice were supplemented with Drosophila melanogaster S2 cells to prevent overdigestion with DNaseI, and the assay was performed as before. DNA was amplified using primers specific for the CD8 promoter and a DNaseI-insensitive region of the gene (Exon V). The graph in Fig. 2 shows that hypersensitivity is observed at the promoter of CD8α in DN3, DN4, and total thymocyte cell populations, but the DN1+2 cell population is insensitive to DNaseI digestion. Thus, the qPCR results confirm the data from the Rag1<sup>−/−</sup> Southern method and extended this analysis by showing that the CD8 locus begins to open from the DN3 stage onwards and that prior to this the locus is fully closed.

**FIGURE 1.** DNaseI hypersensitivity site assay of differentiating T cells. A, Figure showing the CD8 gene complex, with the CD8β gene 32 kb upstream of the CD8α gene, the three CD8-specific clusters of hypersensitive sites (6), and five CD8 enhancers (40, 43). B, DNaseI hypersensitivity site assay of T cell populations from the thymus and periphery of C57BL/10 mice (DN1–3 cells from B6/J Rag1<sup>−/−</sup> MOM mice) showing the appearance of CII-hypersensitive sites with increasing DNaseI concentration (0, 20, 40, and 80 ng DNaseI). The position of the hypersensitive sites CII-1, CII-2, and CII-3 are marked along with the parent bands (indicated by *). The accompanying schematic shows the developmental stages of T cell development. This figure is representative of at least three independent sorting and DNaseI experiments.
To determine whether pre-TCR signaling induces the full opening of the CD8 gene locus, Rag1<sup>2/2</sup> mice were injected i.p. with anti-CD3ε (2C11). Such treatment forces Rag1<sup>2/2</sup> DN3 thymocytes through β selection and enables them to differentiate to DN4 and subsequently to DP cells (44).

**FIGURE 3.** 2C11 i.p. injection of B6/J Rag1<sup>2/2</sup> MOM mice results in thymocytes developing past the DN3 stage and fully opening the CD8 locus. A, FACS analysis of two groups of B6/J Rag1<sup>2/2</sup> MOM mice 36 h after i.p. injection with PBS (left panels) or the anti-CD3ε Ab 2C11 (right panels). Top panels show DN subpopulations defined by CD44 and CD25 (DN1, CD44<sup>+</sup>CD25<sup>+</sup>; DN2, CD44<sup>+</sup>CD25<sup>+</sup>; DN3, CD44<sup>+</sup>CD25<sup>+</sup>; DN4, CD44<sup>+</sup>CD25<sup>+</sup>). Bottom panels show T cell development as defined by CD4 and CD8 (DN, CD4<sup>+</sup>CD8<sup>+</sup>; DP, CD4<sup>+</sup>CD8<sup>+</sup>; CD4 SP, CD4<sup>+</sup>CD8<sup>+</sup>; CD8 SP, CD4<sup>+</sup>CD8<sup>+</sup>). B, DNaseI hypersensitive site analysis of the two groups of B6/J Rag1<sup>2/2</sup> MOM mice 36 h after i.p. injection with PBS or the anti-CD3ε Ab 2C11. Following DNaseI treatment with 0, 20, 40, and 80 ng DNaseI (0, 40, and 80 ng DNaseI for PBS samples), purified DNA was analyzed by real-time PCR. The graph shows samples digested with increasing levels of DNaseI at CII-hypersensitive sites CII-1, CII-2, and CII-3 corrected against a nonhypersensitive region of the locus and expressed as a percentage of input DNA (0 ng DNaseI). The map of CII and the CD8α gene shows the position of the primers. The figure is representative of two independent experiments. 

**FIGURE 2.** The CD8 locus becomes hypersensitive at the DN3 stage. Graph showing DNaseI hypersensitive site analysis of the CD8 locus in DN subpopulations. DN subpopulations were supplemented with Drosophila melanogaster S2 cells and subjected to DNaseI treatment with increasing amounts of DNaseI (0, 20, 40, and 80 ng DNaseI for all subpopulations except for DN1-2 subpopulation in which 20 ng was omitted), and purified DNA was analyzed by real-time PCR. The graph shows hypersensitivity at CII hypersensitive site CII-3 corrected against a nonhypersensitive region of the locus (Exon V) and expressed as a percentage of input DNA (0 ng DNaseI). The map of CII and the CD8α gene shows the position of the primers. The figure is representative of three independent experiments.

D’NaseI analysis of Rag1<sup>2/2</sup> thymocytes forced through β selection

To examine the hypersensitivity of CII during differentiation toward CD8 SP or CD4 SP lineages

To examine the hypersensitivity of CII during differentiation toward CD8 and CD4 lineages, thymocytes and peripheral T cells from C57BL/10 mice were sorted to >96% purity, subjected to DNaseI digestion, and analyzed as described (Fig. 1B, panels 4 and 6). With increasing levels of DNaseI, thymocytes that have just committed to the CD8 lineage (CD8<sup>+</sup>TCR<sup>+</sup>CD24<sup>+</sup>) exhibit all three CII-hypersensitive sites, similar to DP cells (total thymocytes). However, as cells mature and enter the periphery, the CII-2 site is lost, extending previous results (38).
Fig. 1B, panel 5, shows that in CD4+ thymocytes, all three CII-hypersensitive sites are still detectable, albeit at lower intensity than in DP, despite the cessation of CD8 expression. In contrast, in peripheral CD4+ cells (Fig. 1B, panel 7), these hypersensitive sites are undetectable. Thus, it appears that there is a time lag between cessation of CD8 expression and heterochromatinization of the locus, similar to what was seen in the CD4 locus (45).

The H3/H4 tetramer is maintained in the CD8 locus during differentiation, but chromatin in DN cells exhibits bivalency

To gain more detailed information about the chromatin of the CD8 locus during differentiation, ChIP analysis was undertaken. Fig. 4 shows that H3 association with CII and the CD8α gene-body is high and constant as differentiation progresses, indicating that gross nucleosomal structure of the locus is maintained during differentiation.

Activating H3K4me3 and H3K27me3 repressive marks were determined by ChIP analysis (Fig. 5, Supplemental Fig. 3). Fig. 5 shows that the H3K27me3 modification is present at high levels throughout CII and the gene body in DN1+2 and DN3 cells, drops in DN4 cells, and almost disappears in transcribing DP, rising again in cells that cease transcription of CD8 and commit to the CD4 lineage. In contrast, this modification remains low in cells that maintain CD8 expression.

Surprisingly, immunoprecipitation of chromatin with anti-H3K4me3 also showed high levels of this activation mark over an 8-kb region including CII and the CD8α gene in the non-expressing DN1+2, DN3, and DN4 cell populations (Fig. 5). In DP cells, H3K4me3 modification is restricted to the promoter and CD8α gene. Commitment to the CD4 lineage results in very low levels of H3K4me3 throughout the locus, whereas CD8 SP cells retain the high levels of H3K4me3 around the CD8α promoter and gene body. The presence of these modifications at the promoters of Oct4 and Thy1 served as positive and negative controls; in thymocytes, H3K27me3 is enriched at the Oct4 promoter, whereas at the Thy1 promoter, H3 is enriched in the K4me3 modification (Supplemental Fig. 4).

Thus, the DN populations exhibit both the permissive H3K4me3 and the repressive H3K27me3 marks, a phenomenon that was first described in ES cells and termed bivalency (23, 24). Interestingly, this bivalency is restricted only to DN thymocytes and is not described in ES cells and termed bivalency (23, 24). Interestingly, and the repressive H3K27me3 marks, a phenomenon that was first shown in the T cell subsets (Fig. 6, right panel). Similar to Mi-2β, HP1α is associated with the locus mostly in DN1+2 cells, whereas it is absent when CD8 is transcribed and expressed at DP and CD8 SP stages. Cells that have just committed to the CD4 lineage exhibit, again, high levels of HP1α; however, these levels drop in peripheral CD4 SP cells (Fig. 6B, right panel). Another ChIP analysis showing the association between Ikaros, Mi-2β, and HP1α and T cell populations is shown in Supplemental Fig. 5.

Thus, both Mi-2β and HP1α are implicated in negative regulation of the CD8 gene locus during reversible and irreversible silencing in DN and CD4 SP cells, respectively. Thus, both proteins seem to assist in silencing the bivalent locus in DN cells, and HP1α is crucial to the formation of heterochromatin (reviewed in Ref. 50). Association of HP1α with the CD8 locus was examined in the T cell subsets (Fig. 6, right panel). Similar to Mi-2β, HP1α is associated with the locus mostly in DN1+2 cells, whereas it is absent when CD8 is transcribed and expressed at DP and CD8 SP stages. Cells that have just committed to the CD4 lineage exhibit, again, high levels of HP1α; however, these levels drop in peripheral CD4 SP cells (Fig. 6B, right panel). Another ChIP analysis showing the association between Ikaros, Mi-2β, and HP1α and T cell populations is shown in Supplemental Fig. 5.

FIGURE 4. H3 is maintained during transcription. Figure of ChIP analysis of histone H3 showing the levels of H3 along CII and in the CD8α gene in DN1+2, DN3, DN4, DP, CD4 SP, and CD8 SP cells of the thymus and periphery and in splenic B cells. The map of CII shows the position of the primers used to amplify regions of the locus, which are color coded to indicate their positions on the graphs (shown as spheres, primer sets 5’ CII, CII-1, CII-2, CII-3, and Exon V). C>T values from immunoprecipitation with H3 were normalized to C T values from the nonspecific Ab IgG, expressed as percent of input, and plotted on the graphs; results are representative of four independent experiments.
both are removed prior to the locus remodeling at DN3 and DN4 stages. Subsequently, HP1α is involved in initial silencing of the locus in CD4 thymocytes, whereas NuRD resumes its repressive action by being recruited to the locus in peripheral CD4 SP T cells.

**Discussion**

Plasticity in gene expression is a hallmark of developmental processes, and the problem of how genes oscillate between active and inactive states has been a formidable challenge in molecular biology.

The CD8 gene locus offers a useful paradigm to study chromatin involvement in the regulation of a gene that exhibits a complex developmental program of expression. We and others have identified regulatory DNA sequences along the locus that regulates this developmental pattern of expression (6, 7, 37–43). The chromatin structure of these sequences during thymocyte differentiation was examined by DNaseI hypersensitivity, and it was found that the hypervisibility and accessibility are established on the locus before the onset of CD8 transcription and are retained for a short time after the cessation of its expression in the CD4 lineage in the thymus. CD4 cells in the periphery show complete absence of hypervisibility and accessibility are established on the locus before the onset of CD8 transcription and are retained for a short time after the cessation of its expression in the CD4 lineage in the thymus.

![Graph showing the presence of the repressive modification H3K27me3 and the activatory modification H3K4me3 along CII and in the CD8α gene in FACS-sorted DN1+2, DN3, DN4, DP, CD4 SP, and CD8 SP cells of the thymus and periphery. Splenic B cells are shown as control. The position of the primer sets used to analyze CII and CD8α are depicted on the figure as colored spheres and correspond to the colored lines on the graph (primer sets used 5′ CII, CII-1, CII-2, CII-3, and Exon V). C_{T} values from immunoprecipitation with H3K27me3 and H4K4me3 were normalized to C_{T} values from immunoprecipitation with a nonspecific anti-IgG Ab; values were then expressed as percentage of input and plotted on the graphs as shown. Results are representative of three independent experiments, another example of which is shown in Supplemental Fig. 3.](http://www.jimmunol.org/)

<table>
<thead>
<tr>
<th>CD4 SP</th>
<th>CD8 SP</th>
</tr>
</thead>
<tbody>
<tr>
<td>H3 K27me3</td>
<td>H3 K4me3</td>
</tr>
<tr>
<td>Thymus</td>
<td>Periphery</td>
</tr>
<tr>
<td>B cells</td>
<td></td>
</tr>
</tbody>
</table>

**FIGURE 5.** CII exhibits bivalency in DN cells. Graphs showing the presence of the repressive modification H3K27me3 and the activatory modification H3K4me3 along CII and in the CD8α gene in FACS-sorted DN1+2, DN3, DN4, DP, CD4 SP, and CD8 SP cells of the thymus and periphery. Splenic B cells are shown as control. The position of the primer sets used to analyze CII and CD8α are depicted on the figure as colored spheres and correspond to the colored lines on the graph (primer sets used 5′ CII, CII-1, CII-2, CII-3, and Exon V). C_{T} values from immunoprecipitation with H3K27me3 and H4K4me3 were normalized to C_{T} values from immunoprecipitation with a nonspecific anti-IgG Ab; values were then expressed as percentage of input and plotted on the graphs as shown. Results are representative of three independent experiments, another example of which is shown in Supplemental Fig. 3.
last event that occurs during the on/off sequence of CD8 gene expression. This is in agreement with other examples in the literature that suggest that chromatin accessibility is established shortly before the onset of transcription (23, 24, 51).

Our data revealed that remodeling is a gradual process and dependent on external stimuli. Thus, whereas the CD8 promoter is inaccessible in the early stages of differentiation (DN1 + DN2), the promoter shows signs of remodeling at the DN3 stage. Remarkably, the establishment of full accessibility at the rest of the regulatory elements seems to require signals from the pre-TCR. Recent data have shown that the pre-TcR dimerizes autonomously to TCRβ, acting as a crucial checkpoint to ensure the correct rearrangement and folding of TCRβ and enabling subsequent signaling through the pre-TCR (52). It could be envisaged that such signaling mechanisms could be translated to chromatin modifications.

To address what epigenetic modifications are associated with these changes, we examined the histone code on the regulatory elements and the gene itself during the different stages of development. It was shown that in CD8-expressing cells, the locus has open chromatin histone marks (H3K4me3) on a narrow region (∼2 kb) comprising the promoter and the gene. In contrast, CD4 cells establish negative histone marks throughout the locus following commitment of DP cells to this lineage. Remarkably, however, in the DN stage when the chromatin of the locus is being remodeled to become accessible, we observed the existence of both positive (H3K4me3) and negative (H3K27me3) marks along a widespread region of at least 8 kb covering the 5′ regulatory elements as well as the body of the gene. Although it has been technically impossible to ascertain that the two modifications are present on the same stretch of chromatin (24), our data are consistent with

FIGURE 6. Ikaros is associated with the locus throughout development, whereas negative regulators associate with the locus when CD8 is not expressed. A, Figure showing the association of Ikaros (left panel), Mi-2β (middle panel), and HP1α (right panel) with CII and the CD8 gene in DN1+2, DN3, DN4, and DP thymocytes. C_7 values from immunoprecipitation with anti-Ikaros, anti–Mi-2β, and anti-HP1α Abs were normalized to IgG, expressed as percentage of input, and plotted on the graphs. B, Graphs showing the association of Ikaros (left panel), Mi-2β (middle panel), and HP1α (right panel) with CII and the CD8 gene in CD4 SP and CD8 SP cells of the thymus and periphery. CD4 SP cells are represented by green bars, and CD8 SP cells are represented by red bars. Normalization of C_7 values is as described in A. The map of CII shows the position of the primers used to amplify regions of the locus, which are color coded to indicate their positions on the graphs (shown as spheres; primer sets 5′ CII, CII-1, CII-2, CII-3, and Exon V). The results are representative of three independent experiments, another example of which is shown in Supplemental Fig. 5.

FIGURE 6. Ikaros is associated with the locus throughout development, whereas negative regulators associate with the locus when CD8 is not expressed. A, Figure showing the association of Ikaros (left panel), Mi-2β (middle panel), and HP1α (right panel) with CII and the CD8 gene in DN1+2, DN3, DN4, and DP thymocytes. C_7 values from immunoprecipitation with anti-Ikaros, anti–Mi-2β, and anti-HP1α Abs were normalized to IgG, expressed as percentage of input, and plotted on the graphs. B, Graphs showing the association of Ikaros (left panel), Mi-2β (middle panel), and HP1α (right panel) with CII and the CD8 gene in CD4 SP and CD8 SP cells of the thymus and periphery. CD4 SP cells are represented by green bars, and CD8 SP cells are represented by red bars. Normalization of C_7 values is as described in A. The map of CII shows the position of the primers used to amplify regions of the locus, which are color coded to indicate their positions on the graphs (shown as spheres; primer sets 5′ CII, CII-1, CII-2, CII-3, and Exon V). The results are representative of three independent experiments, another example of which is shown in Supplemental Fig. 5.
a hypothesis that in the stages before commitment to active transcription, the locus acquires a poised, accessible, but nontranscribing configuration. This is characterized, on one hand, by histone marks that can attract activating remodeling complexes (possibly involving Trx group) and, on the other hand, by the simultaneous acquisition of the repressive modification H3K27me3 (possibly via PcG proteins) that can impose a silencing conformation. Interestingly, this bivalency appears to occupy the whole gene locus (~8 kb) and is in agreement with observations made in ES/pluripotent cells in which H3K4me3 was found to cover large areas of bivalent domains (24) as opposed to the narrow distribution seen on transcribing genes.

It is thought that bivalency in a locus resolves in a stably active or stably inactive conformation by the loss of one of the bivalent marks in subsequent differentiation stages (24). Indeed, following pre-CR signaling and progression to the DN4, and ultimately DP stage, the CD8 locus loses the H3K27me3 mark while retaining the H3K4me3 mark on the promoter region of the gene in the DP and CD8 SP stages. However, this state is not permanent, as DP cells that commit to the CD4 lineage lose this activation mark and reacquire high levels of the H3K27me3 modification accompanied by silencing of the gene. This is analogous to what has been described by Golob et al. (53) on the brachyury locus, in which a bivalent state is resolved first into an active transcribing configuration, which turns into an inactive configuration in the subsequent developmental stages, indicating, as predicted (32), that bivalency resolution does not have to be a permanent decision. Interestingly, bivalency and its resolution were also observed on master gene loci during fate determination of differentiating CD4 T cells following appropriate stimulation, also indicating that poised configuration can underlie rapid responses to environmental signals (32, 54). However, bivalency is not the only mechanism employed by lymphocytes to poise transcription as observed in effector gene loci in memory CD8+ T cells (55).

It is still not clear whether the bivalency observed in this study plays the same role as in the other situations in which it has been described (56). Questions that had concerned the field are how early in development these bivalent states are achieved, how they are resolved, and how this resolution can be reversed in subsequent differentiation stages. It has been reported in genomewide studies of ES cells that the murine CD8α locus carries the H3K27me3 modification (56, 57), whereas one of these studies also reports bivalency on the human CD8α gene in these cells. In this study, we also show that pre-TCR signaling is closely linked with the resolution of this bivalency at the DN3 to DN4 transition stage. Although bivalency seems to be a mechanism by which CD8 expression is regulated in early thymocytes, it may not be a universal mechanism, as the regulation of the CD4 gene (58) and our control genes indicate. Bivalency may provide an additional level of regulation at this stage, as transcription of the CD8 gene is controlled by enhancers, whereas CD4 is regulated by silencers. Interestingly, naïve CD4 cells exhibit bivalency later in their differentiation (54); the establishment of bivalent chromatin may provide a mechanism by which gene regulation can be regulated at branch point decisions.

Through these changes, such as locus accessibility, establishment of bivalency, and its resolution after pre-TCR signaling, Ikaros is found on the CD8 locus regardless of expression status. As Ikaros can associate and recruit active (BAP) or repressive (NuRD) complexes, activation or silencing may depend on the complex it recruits to the locus. This is especially interesting in the light of the antagonistic role of Swi/Snf and NuRD reported in LPS-induced macrophages (59). Indeed, in CD8 nonexpressing cell populations, the region occupied by Ikaros is also occupied by Mi-2β, which is the major ATPase of the suppressing NuRD chromatin remodeling complex. Such dual function of a DNA-binding factor determined by the activity of the associated remodeling complexes has also been described for the Pax5 gene (60).

The outcome of Ikaros associating with the CD8 locus in nonexpressing cells is as yet unclear. Because a high proportion of Ikaros in T cells is associated with the NuRD complex (47), it is possible that Ikaros recruits the complex to the locus to repress expression of CD8. However, in light of the fact that in the CD4 gene locus Ikaros and Mi-2β antagonize each other (29) and that Ikaros is involved in the activation of the CD8 locus (7), it is also possible that Ikaros attempts to activate the locus, with NuRD and HP1α antagonizing this in DN and CD4 SP cells. It would be interesting to determine how important Ikaros is to establishing the histone code of the CD8 locus during development; unfortunately, the phenotype of Ikaros knockout mice makes their use in determining this impractical (61).

Although our study has focused on histone tail modifications and chromatin remodelers, the demethylation of CpG islands also plays an important role in DNA accessibility, transcription factor binding, and subsequent transcription of a gene. Analysis of CpG methylation in the CD8 locus determined that there was a significant decrease in methylated CpG at CII-1 and CII-2 in CD8-expressing cells (11). Demethylation of CpG will alter the accessibility of binding sites, and acting in concert with other changes in the locus, such as the reduction in methylation of H3K27 and loss of negative regulators Mi-2β and HP1, may enable binding of chromatin remodelers and transcription factors resulting in nucleosome remodeling, PolII recruitment, and subsequent transcription of the CD8 gene.

Our results taken together indicate that the appropriate silencing of the CD8 gene during thymocyte differentiation is achieved by a variety of chromatin regulatory mechanisms. Thus, in DN stages, the locus is silenced by the concerted action of either Ikaros recruiting Mi-2β or by Mi-2β antagonizing Ikaros, the presence of HP1α, and the negative histone mark of H3K27me3, while at the same time maintaining a poised configuration as indicated by the H3K4me3 mark. Full accessibility and activation of the locus is achieved by the locus after the β selection point by losing the negative histone mark and the removal of Mi-2β and HP1α from its chromatin. In the thymus, commitment to the CD4 lineage results in the binding of HP1α and re-establishment of negative histone marks. Interestingly, in the peripheral CD4 T cells, HP1α is removed, and the silencing of the CD8 gene appears to be maintained by Mi-2β.

In conclusion, the data presented in this study are consistent with a hypothesis that bivalent chromatin is a basic mechanism that underlies gene regulation at key points in thymocyte differentiation and lineage fate decisions. In addition to its role in the regulation of expression of developmental genes in pluripotent cells (embryonic stem cells, neural progenitors) (23, 24) and conferring plasticity in mature cells that need to respond rapidly to external stimuli (naïve Th cells) (25), it also appears to be involved in the regulation of signature genes that are switched on and off during fate decision points of differentiating lineage committed cells.

Acknowledgments
We thank Dr. Katie Foster, Dr. Henrique Veiga-Fernandes, and Dr. Valentinio Parravicini for i.p. injections of B6/J Rag1−/− MOM mice and Dr. Jacqueline Mermod, King’s College (London, U.K.) for the Oct4 primer sequence. We also thank the members of the Divisions of Molecular Immunology and Immune Cell Biology at the NIMR for helpful discussions as well as Michelle Burke for excellent secretarial assistance and all of the members of the sorting and animal facilities at the NIMR.
Disclosures
The authors have no financial conflicts of interest.

References


